Recombinant trail: a synergistic effect in myeloid leukemias
نویسندگان
چکیده
منابع مشابه
Recombinant trail: a synergistic effect in myeloid leukemias
The tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL/Apo-2L) is a member of the TNF superfamily that trigger and activate 2 death receptors, DR4 and DR5, and 2 decoy receptors, DcR1 and DcR2. Several studies demonstrated that TRAIL in monotherapy can induces cancer cell death cells, but few have been done in leukemias in combination with conventional drugs. The aim of this w...
متن کاملTargeting Ras in myeloid leukemias.
Ras proteins normally relay growth-promoting signals from many activated cell surface receptors, and they are altered by oncogenic point mutations in approximately 30% of human cancers. Activating KRAS and NRAS mutations are especially common in malignancies of the pancreas, lung, and colon, and in myeloid leukemia. Here, we discuss general strategies for targeting hyperactive Ras signaling in ...
متن کاملSorafenib and TRAIL have synergistic effect on hepatocellular carcinoma.
A multi-kinase inhibitor, sorafenib, was recently approved and is currently recommended for the treatment of advanced hepatocellular carcinoma (HCC). However, HCC treatment outcomes are still poor and necessitate improvement. Therefore, we investigated the influence of sorafenib in combination with each of cytotoxic chemotherapy agents, hypoxia or...
متن کاملEffect of human recombinant granulocyte colony-stimulating factor on induction of myeloid leukemias by X-irradiation in mice.
Hematopoietic suppression is one of the serious problems induced by whole body irradiation. Granulocyte colony-stimulating factor (G-CSF) stimulates the progenitors of granulocytes and accelerates their recovery from bone marrow suppression induced by cytotoxic chemotherapy or radiation. On the other hand, G-CSF stimulates proliferation of myeloid leukemia cells as well as normal granulocytes i...
متن کاملTherapy-Related Acute Myeloid Leukemias
Therapy-related acute myeloid leukemia (t-AML) is a heterogeneous group of myeloid neo‐ plasms occurring as an overwhelming complication in patients receiving previous cytotoxic chemotherapy and/or radiation therapy used to treat haematopoietic or solid malignancies or associated with immunosuppressive treatment for non-neoplastic rheumatologic/autoim‐ mune diseases or solid organ transplantati...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMC Proceedings
سال: 2010
ISSN: 1753-6561
DOI: 10.1186/1753-6561-4-s2-p46